Improving Patient Assessment After Acute Kidney Injury (AKI)
ConditionAcute Kidney Injury
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-85
SponsorUniversity of Nottingham
About this trial
The goal of this clinical trial is to improve patient care after acute kidney injury (AKI). It has three related parts. The main questions it aims to answer are:
1. Is creatinine or cystatin a more reliable assessment of kidney function after AKI? 2. What are the experiences of patients after AKI? 3. What interventions should be recommended to improve assessment and support of patients after AKI?
Participants will be asked to do one or more of:
* blood tests to measure kidney function in different ways * have measurement of their body composition * complete questionnaires about their symptoms * have an interview with a researcher about their experiences * discussion to develop an action plan based on findings
Eligibility criteria
Qualifiers
Age 18-85 years
AKI stage 2 or 3 during hospital admission OR AKI stage 1 of at least 7 days duration during hospital admission
60-90 days after peak creatinine Qualitative interview workstream
Age 18-85 years
Disqualifiers
Inability to give informed consent
No baseline creatinine available in previous 12 months
Pregnancy or breastfeeding
Current treatment with dialysis
Trial design
Treatments tested in this trial
- Iohexol renal clearance measurement
- Cystatin C
- Creatinine
- Semi structured interview
- Participatory workshop
- Metagenome analysis
- Bioimpedance analysis
- Patient reported outcome measures
- Measurement of physical performance
Treatment groups
100 Participants
are divided into 3 treatment groupsSponsors and collaborators
University of Nottingham
Lead sponsor
University Hospitals of Derby and Burton NHS Foundation Trust
Collaborator
Source ClinicalTrials.gov